HYPERFINE, INC.


Associated tags: FDA, Jonathan Rothberg, Magnetic resonance imaging, Swoop, National Medal, DNA, Patient, Operating, MRI, Therapy, Intensive care medicine, Butterfly network, Hyperfine structure, Medical imaging, Health, Medical Devices, Research

Locations: UNITED STATES, NORTH AMERICA, CONNECTICUT

Hyperfine, Inc. Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
Marketing, Hyperfine structure, FDA, News, Research, Baozou Big News Events, Video game, Reinsurance, Cryptocurrency

Gross margin for the third quarter of 2023 was $1.12 million, resulting in a 48% gross margin, compared to $0.69 million in the third quarter of 2022.

Key Points: 
  • Gross margin for the third quarter of 2023 was $1.12 million, resulting in a 48% gross margin, compared to $0.69 million in the third quarter of 2022.
  • Research and development expenses for the third quarter of 2023 were $5.74 million, compared to $7.34 million in the third quarter of 2022.
  • Sales, marketing, general, and administrative expenses for the third quarter of 2023 were $7.14 million, compared to $6.63 million in the third quarter of 2022.
  • ET on Thursday, November 9, 2023, to discuss its third quarter 2023 financial results and provide a business update.

Hyperfine, Inc. Announces Presentations on Clinical Advancements at RSNA 2023

Retrieved on: 
Monday, November 20, 2023
Medical Devices, Health, Neurology, Health Technology, Radiology, Biotechnology, RSNA, Hyperfine structure, Physician, Conference, Multimedia, Diagnosis, FDA, Medical imaging

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that has redefined brain imaging with the world’s first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system—the Swoop® system—today announced that three scientific sessions highlighting ultra-low-field imaging data will be presented at the Radiological Society of North America (RSNA) 2023 Annual Meeting in Chicago.

Key Points: 
  • Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that has redefined brain imaging with the world’s first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system—the Swoop® system—today announced that three scientific sessions highlighting ultra-low-field imaging data will be presented at the Radiological Society of North America (RSNA) 2023 Annual Meeting in Chicago.
  • These studies analyzed how portable MR brain imaging may assist physicians in the diagnosis and management of neurological conditions in critical care settings.
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20231120443877/en/
    Hyperfine, Inc. has redefined brain imaging with the world’s first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system—the Swoop® system (Photo: Business Wire)
    Conference attendees can learn more during the presentations listed below.

Hyperfine, Inc. to Present at the Piper Sandler 35th Annual Healthcare Conference

Retrieved on: 
Thursday, November 16, 2023
Health, Medical Devices, Hospitals, Health Technology, General Health, Radiology, Biotechnology, Hyperfine structure, Conference, FDA

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that has redefined brain imaging with the world’s first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system—the Swoop® system—today announced plans to present at the upcoming Piper Sandler 35th Annual Healthcare Conference, in New York.

Key Points: 
  • Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that has redefined brain imaging with the world’s first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system—the Swoop® system—today announced plans to present at the upcoming Piper Sandler 35th Annual Healthcare Conference, in New York.
  • Members of management are scheduled to present on Thursday, November 30, 2023, at 9:30 am PT.
  • A live webcast of the event, as well as an archived recording will be available on the “Investors” section of the company’s website at: investors.hyperfine.io .
  • The webcasts will be archived and available for replay for at least 90 days after the event.

Observational Study Finds That Hyperfine, Inc. Portable MR Brain Imaging System Assists Clinicians in Early Detection of Acute Brain Injury in ECMO Patients

Retrieved on: 
Thursday, November 2, 2023
Health Technology, Health, Neurology, Medical Devices, Hyperfine structure, Stroke, FDA, MRI, Extracorporeal membrane oxygenation, Incidence, Brain damage, Mortality, ABI, Multimedia, CT, Brain, ECMO, Medical imaging, Patient, MD

The study evaluated the feasibility of using portable MR brain imaging for monitoring patients during ECMO use, highlighting its potential advantage in providing early visualization of ischemic stroke compared to computerized tomography (CT) scans.

Key Points: 
  • The study evaluated the feasibility of using portable MR brain imaging for monitoring patients during ECMO use, highlighting its potential advantage in providing early visualization of ischemic stroke compared to computerized tomography (CT) scans.
  • The initial findings of this study demonstrate the feasibility of using portable MR brain imaging with adult ECMO patients.
  • It concludes that the incidence of acute brain injury was high, with ischemic stroke being the most common type of injury.
  • “This may be particularly important when you consider mortality rates due to acute brain injury in ECMO patients and emphasizes the need for early and accurate neuromonitoring.”
    “The study’s findings are very encouraging, especially as they relate to the benefits of using the Swoop® portable brain imaging system for early assessment of acute brain injury in patients being treated with ECMO.

Hyperfine, Inc. to Announce Third Quarter Financial Results on November 9, 2023

Retrieved on: 
Thursday, October 19, 2023
Health, Medical Devices, Technology, General Health, Pharmaceutical, Hardware, Biotechnology, Hyperfine structure, FDA, Medical imaging, Online shopping

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that has redefined brain imaging with the world’s first FDA-cleared portable magnetic resonance brain imaging system—the Swoop® system—today announced that it will report financial results for the third quarter 2023 on Thursday, November 9, 2023.

Key Points: 
  • Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that has redefined brain imaging with the world’s first FDA-cleared portable magnetic resonance brain imaging system—the Swoop® system—today announced that it will report financial results for the third quarter 2023 on Thursday, November 9, 2023.
  • Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
  • A live audio webcast and an archive of the presentation will be available through the Investors page of Hyperfine, Inc.’s corporate website at https://investors.hyperfine.io/ .
  • Participants are encouraged to register more than 15 minutes before the start of the call.

Hyperfine, Inc. Announces Promotions of Two Key Clinical Affairs Executives

Retrieved on: 
Tuesday, October 10, 2023
Radiology, Health, Medical Devices, Neuroscience, University School, DRS, SUNY Downstate Medical Center, Senior, Neuroradiology, Google Images, Stroke, Politics, Society, Book, University, Emory University, Injury, Gary Knopp, Davos, Neuroimaging, American Board of Commissioners for Foreign Missions, FDA, Georgetown University, American Board of Radiology, Philips, Medical imaging, Nursing, Biology, Medtronic, Hyperfine structure, Science

Knopp and Truwit will be taking on new roles as vice president of medical affairs and vice president of scientific affairs, respectively.

Key Points: 
  • Knopp and Truwit will be taking on new roles as vice president of medical affairs and vice president of scientific affairs, respectively.
  • Dr. Knopp joined Hyperfine, Inc. in 2021 and brings three decades of experience in radiology, neuroradiology, and MR imaging.
  • In the role of vice president of scientific affairs, Dr. Chip Truwit will spearhead clinical innovation projects, supporting the Swoop® system’s continued advancement.
  • Dr. Chip Truwit joined Hyperfine, Inc. in 2022 and has over three decades of experience in academic and clinical radiology.

Hyperfine, Inc. Receives FDA Clearance for Updated AI-powered Software with Improved Image Quality for All Swoop® System Sequences

Retrieved on: 
Monday, October 9, 2023
Neurology, Software, Health, FDA, Artificial Intelligence, Medical Devices, Health Technology, Technology, Deep learning, DWI, Patient, FLAIR, Brain, Hyperfine structure, Medical imaging

Built on a robust AI foundation, the latest software brings image quality enhancements to the Swoop® system’s diffusion-weighted imaging (DWI) sequence.

Key Points: 
  • Built on a robust AI foundation, the latest software brings image quality enhancements to the Swoop® system’s diffusion-weighted imaging (DWI) sequence.
  • With this latest software update, Hyperfine, Inc. expands the Swoop® system’s AI denoising capabilities by incorporating advanced image post-processing into the DWI sequence.
  • Denoising enables a crisper image that potentially helps clinicians more accurately diagnose, treat, and monitor patients undergoing brain imaging.
  • More than milestones, it's about reshaping patient care, empowering clinicians, and advancing brain imaging.”
    Hyperfine, Inc. will roll out the updated Swoop® system software in the coming months.

Hyperfine, Inc. to Present at Gilmartin Group Emerging Growth Showcase

Retrieved on: 
Thursday, September 7, 2023
Radiology, Health, Medical Devices, FDA, Hyperfine structure, Medical imaging, Convenience food

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable magnetic resonance brain imaging system, today announced plans to participate at the upcoming Gilmartin Group Emerging Growth Showcase, taking place virtually.

Key Points: 
  • Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable magnetic resonance brain imaging system, today announced plans to participate at the upcoming Gilmartin Group Emerging Growth Showcase, taking place virtually.
  • Members of management are scheduled to present on Thursday, September 21, 2023, at 1:00 pm ET.
  • For more information about the Swoop® Portable MR Imaging® system, please visit hyperfine.io .

Hyperfine, Inc. Reports Second Quarter 2023 Financial Results

Retrieved on: 
Monday, August 14, 2023
Stroke, Diagnosis, MRI, Research, Baozou Big News Events, FDA, PMR, Observational study, Patient, ACTION, News, Marketing, Pharmaceutical industry, Video game, Reinsurance, Cryptocurrency, Hyperfine structure

Gross margin for the second quarter of 2023 was $1.44 million, compared to $(0.17) million in the second quarter of 2022.

Key Points: 
  • Gross margin for the second quarter of 2023 was $1.44 million, compared to $(0.17) million in the second quarter of 2022.
  • Research and development expenses for the second quarter of 2023 were $5.33 million, compared to $7.27 million in the second quarter of 2022.
  • Sales, general, and administrative expenses for the second quarter of 2023 were $7.81 million, compared to $15.76 million in the second quarter of 2022.
  • ET on Monday, August 14, 2023, to discuss its second quarter 2023 financial results and provide a business update.

Enrollment Completed for HOPE PMR Pediatric Hydrocephalus Study Using Hyperfine, Inc. Portable MR Imaging® System

Retrieved on: 
Wednesday, August 9, 2023
Medical Devices, Health, Neurology, Health Technology, Research, Science, Radiation, PMR, HOPE, Portable, Multimedia, Index, MRI, Hydrocephalus, Data analysis, Patient, Neurosurgery, Hospital, Pediatric neurosurgery, FDA, Nationwide, Medical imaging, Nursing, Hyperfine structure

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable magnetic resonance brain imaging system, today announced completed enrollment for the multi-site observational study, HOPE PMR (Portable MRI for Children with Neurological Injury—A Pilot Study using Hydrocephalus as an Index Condition).

Key Points: 
  • Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable magnetic resonance brain imaging system, today announced completed enrollment for the multi-site observational study, HOPE PMR (Portable MRI for Children with Neurological Injury—A Pilot Study using Hydrocephalus as an Index Condition).
  • The study used pediatric hydrocephalus as an index condition to assess if Swoop® system images can be used to accurately detect shunt malfunctions and assess ventricular size.
  • "The Swoop® system represents a promising shift in brain imaging.
  • Our collaboration with Hyperfine, Inc. paves the way for improvements in brain imaging, benefiting this vulnerable patient population."